MétaCan
Menu
Retour à la cohorte
Enregistrement W2144892874 · doi:10.1176/appi.pn.2014.10b3

Long-Term Use of Benzodiazepines May Be Linked to Alzheimer’s

2014· article· en· W2144892874 sur OpenAlexaboutno aff
Vabren Watts

Notice bibliographique

RevuePsychiatric News · 2014
Typearticle
Langueen
DomaineMedicine
ThématiqueDiet and metabolism studies
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésTerm (time)Medicine

Résumé

récupéré en direct d'OpenAlex

Back to table of contents Previous article Next article Clinical and Research NewsFull AccessLong-Term Use of Benzodiazepines May Be Linked to Alzheimer'sVabren WattsVabren WattsPublished Online:16 Oct 2014https://doi.org/10.1176/appi.pn.2014.10b3AbstractResearchers caution physicians to take more care when prescribing benzodiazepines.While research has shown an association between benzodiazepines and acute cognitive function, evidence for a link between the anxiolytic medications and an increased risk for certain neurocognitive disorders remains unclear. Kristo-Gothard Hunor/ShutterstockResearchers from the University of Bordeaux in France and the University of Montreal conducted a study to investigate the relationship between the risk for Alzheimer's disease (AD) and long-term exposure to benzodiazepines, as well as any potential dose-response relationship. "Prevalence of [benzodiazepines] use among elderly patients is consistently high in developed countries … [ranging] from 7 percent to 43 percent," noted the researchers. International guidelines recommend short-term use of the drug, mainly because of withdrawal symptoms that make discontinuation problematic; however, the study noted, use of benzodiazepines is often long term in older people."Somewhere along the way, the message got lost, and patients were allowed to use benzodiazepines for months and years," said Mohit P. Chopra, M.D., a member of APA's Council on Geriatric Psychiatry. Chopra, who was not involved with the study, told Psychiatric News that guidelines recommend that the anxiolytic and insomnia medicines are to be used on a daily basis for no longer than four to six weeks.In 2012, the American Geriatric Society (AGS) updated its list of potentially inappropriate drugs for older adults to include benzodiazepines, precisely because of cognitive side effects—yet, AGS reported, almost 50 percent of older adults who have been prescribed benzodiazepines continue to use such drugs without any formal monitoring system to indicate how they are responding to the drugs. In the current study, to highlight the potential consequences associated with long-term use of benzodiazepines on neurocognitive function in the elderly, the researchers gathered data from 1,796 people aged 66 and older with a first diagnosis for AD and 7,184 age-matched cognitively healthy controls. The study analyzed participants' prescription and medical records dating back six years prior to the AD diagnosis.The results, published in BMJ September 9, showed that use of benzodiazepines for three months or more was associated with an increased risk—up to 51 percent—for AD. The association increased even more with longer exposure. In addition, the use of long-acting forms of benzodiazepines increased risk for AD by 19 percent more than that of short-acting versions. The results were sustained after adjusting for anxiety, depression, and sleep disorders among the study subjects.The researchers concluded that benzodiazepines are "indisputably valuable tools for managing anxiety disorders and transient insomnia," but warned that treatment with these medications should be used within the time parameters set by international guidelines.Davangere Devanand, M.D., director of the geriatric psychiatry program at Columbia University, agreed with this recommendation."These findings emphasize the importance of restricting the use of benzodiazepines in the elderly population," said Devanand in an interview with Psychiatric News. "Benzodiazepines are known to be associated with an increased risk of worsening cognition … even in cognitively normal elderly subjects." Devanand said that in such situation, it would be would be best to taper and cease patients' use of the benzodiazepine while reevaluating cognition functioning. "If the cognitive decline is due to benzodiazepines, and the patient does not have an underlying dementia such as Alzheimer's disease, the cognitive decline should reverse after stopping the treatment." Devanand stressed that in order to ensure that prescribers are not putting their patients at risk for the onset of neurocognitive disorders, "benzodiazepines should be prescribed sparingly and for short periods." ■An abstract of "Benzodiazepine Use and Risk of Dementia: Prospective Population-Based Study" can be accessed here. ISSUES NewArchived

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,112
Score d'incertitude au seuil0,649

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0010,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,068
Tête enseignante GPT0,328
Écart entre enseignants0,260 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2014
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revuePsychiatric NewsMême sujetDiet and metabolism studiesTravaux en français237 207